A drug discovery platform dedicated to the identification of new clinical candidates in oncology
C3D, Center for Discovery and Development is an academic drug discovery team created to fill the translational gap in oncology between fundamental research and patients. The aim of this platform is to develop drug discovery programs based on validated target or biological pathways identified by basic researchers. C3D follows projects from the early exploratory stages their entry into clinical trials.
To accelerate the transfer of academic research programs towards the clinic
To create developmental partnerships between academia and pharmaceutical industry
To support your screening and drug discovery development (small molecules; antibodies)
CYP450 inhibition; cardiac toxicity (in vitro hERG)
Hit identification, Hit to lead, pharmacological profiling (in vitro, in vivo), Toxicology, Early-ADME, Medicinal Chemistry, preclinical development
Our chemical libraries:
Prestwick library, 1,200 FDA approved compounds; Core library of 52,000 « drug like » compounds; Protein/protein inhibition library: 13,000 compounds.
Natural like compounds: 1,200; Kinase library (approved or under development drugs): 590 compounds
Automated liquid handling (robotic platform TECAN EVO150), Multi-technology microplate readers (96 – 384 wells), HPLC chains coupled to mass spectrometers, HP D300 dispenser for titration (TECAN), HCS platform: operetta CLS Perkin Elmer
Stéphane Giraud, PhD
Scientific Director, Center for Drug Discovery and Development email@example.com
Centre Léon Bérard, Bât. Cheney B.
28 rue Laennec 69373 Lyon Cedex 08
Tel : 33 (0)4 26 55 67 74
We use coockies